Sunobinop

Sunobinop (developmental code names V117957; IMB-115) is a high affinity small molecule nociceptin receptor partial agonist. As of February 2024, it is under clinical investigation for the treatment of insomnia, alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.
Wikipedia contributors, "Sunobinop", Wikipedia, revision 1332979819, retrieved 20 November 2026, source, CC BY-SA 4.0.